Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
General transcription factor IIA subunit 1 (GTF2A1) is a core component of the eukaryotic transcription machinery required for accurate initiation of transcription on TATA-containing class II genes by RNA polymerase II[1][5][7]. It forms part of the TFIIA complex, consisting of alpha (35 kDa), beta (19 kDa)—both encoded together and produced by posttranslational cleavage—and gamma (12 kDa) subunits[1][5]. GTF2A1 interacts with the TATA-binding protein (TBP) and stabilizes the preinitiation complex, facilitating promoter recognition and supporting transcriptional activation[1][5][7]. It plays a role in assembling the basal transcription complex and regulating gene expression, but is not generally considered a direct therapeutic target, and no drugs are known to specifically interact with it[1][2][5]. GTF2A1 is evolutionarily conserved and localizes primarily to the nucleoplasm and cytosol[2][6]. Its dysfunction could, in principle, disrupt normal gene expression and cellular function, but there are no established disease associations, biomarkers, or unique safety concerns described for this factor at present[1][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on General transcription factor IIA subunit 1 (GTF2A1).